Sign in
Not yet taking people in NetherlandsPhase 4

Filgotinib versus steroid injection bridging in newly diagnosed rheumatoid arthritis

Compares filgotinib tablets with a steroid injection to bridge early rheumatoid arthritis treatment.

Key facts

Who runs it
Medisch Spectrum Twente
Where
Enschede, NetherlandsSee the site
Registry title
Filgotinib bridging in newly diagnosed rheumatoid arthritis patients (FAST RA trial); A pragmatic randomized controlled non-inferiority low intervention clinical trial
Status
Not yet recruiting
Phase
Phase 4
People taking part
168 people, planned
Started
1 Jan 2025
Expected to end
1 Jan 2027
Type of study
Interventional
Record updated
16 January 2025

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with newly diagnosed rheumatoid arthritis who have never taken disease-modifying drugs (DMARDs). It compares two short-term treatments given at the start of methotrexate and hydroxychloroquine therapy.

Age
18 to 64 years
Sex
All sexes can join.
Disease stage
Newly diagnosed rheumatoid arthritis, diagnosed by a rheumatologist, with a DAS28-CRP score above 2.6 at the start.
Earlier treatment
Must never have taken DMARDs. No corticosteroids in the last three months.

Main reasons for not taking part

  • Current or earlier treatment with DMARDs
  • Risk of cardiovascular disease
  • Risk of cancer, including current or long-term smoking
  • Pregnancy, planned pregnancy or planning to father a child
  • Corticosteroid use in the last three months

The registry criteria, word for word

Show all 12 criteriaShow less

Who can take part

  • Newly diagnosed rheumatoid arthritis patients according to a rheumatologist
  • DMARD-naive
  • Age 18 – 64 years old
  • DAS28-CRP > 2.6 at the start of the study
  • Dutch proficiency
  • Signed informed consent

Who cannot take part

  • Current or prior treatment with DMARDs
  • Corticosteroid use in the last three months
  • Risk of cardiovascular diseases
  • Risk of malignancies, including current smoking of having smoked for a long time
  • (Planned) pregnancy or planning to father a child
  • Contra-indications for methotrexate, adalimumab, tocilizumab, hydroxychloroquine, triamcinolone, filgotinib or folic acid (protocol section 4.3)

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 18 and 64 years old?

Where in Netherlands

  • Medisch Spectrum TwenteEnschede, NetherlandsNot yet recruiting

About the trial

What the trial wants to find out

To investigate non-inferiority and potential superiority in achieving disease activity remission at 3 months of bridging with a JAK inhibitor (Filgotinib 200 mg once daily for 3 months) versus bridging with corticosteroids (triamcinolone 120 mg single dose im) when starting with methotrexate and hydroxychloroquine therapy in rheumatoid arthritis patients.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record

Print a page for my doctor

Data and sources

Registry record
Listed on the EU's official list of trials (CTIS).
Official title
Filgotinib bridging in newly diagnosed rheumatoid arthritis patients (FAST RA trial); A pragmatic randomized controlled non-inferiority low intervention clinical trial
Plain-language title
Filgotinib versus steroid injection bridging in newly diagnosed rheumatoid arthritisGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 9 November 2026.
Fit questions
Built from 2024-517112-30-00, who can take part
Record updated
16 January 2025